Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet2010; 375: 2215–2222.
2.
RidkerPM. Should aspirin be used for primary prevention in the post-statin era?N Engl J Med2018; 379: 1572–1574.
3.
PiepoliMFHoesAWAgewallS, et al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J2016; 37: 2315–2381.
4.
De BerardisGSaccoMStrippoliGF, et al.Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trials. BMJ2009; 339: b4531.
5.
The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med2018; 379: 1529–1539.
6.
LiberatiAAltmanDGTetzlaffJ, et al.The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med2009; 151: w1–w30.
7.
RendaGdi NicolaMDe CaterinaR. Net clinical benefit of non-vitamin K Antagonist oral anticoagulants versus warfarin in phase III atrial fibrillation trials. Am J Med2015; 128: 1007–14.e2.
8.
ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA1992; 268: 1292–1300.
